Novo Nordisk Pharmatech to Exhibit at CPHI North America
Novo Nordisk Pharmatech has announced it will be attending CPhI North America, the meeting place for those seeking powerful partnerships to illuminate the path towards high-growth in the pharmaceutical industry.
The inaugural event will take place from 16 May to 18 May at the Pennsylvania Convention Center in Philadelphia. It will occur adjacent to the 32nd edition of Informex, the home of fine and specialty chemicals. Novo Nordisk Pharmatech looks forward to meeting you at booth #2358, where it will be co-standing with its US distributor Brenntag.
With more than 65 years in the Quats industry, Novo Nordisk has experience in manufacturing many different types of Quats products. The company understands the importance of using best quality ingredients in pharmaceutical products and it offers some of the highest-quality products on the market.
All Novo Nordisk Pharmatech’s Quats offerings meet current good manufacturing practice (cGMP) standards and are produced according to ICH Q7, including validated processes, complete traceability, and complete documentation.
An innovative synthesis process makes Novo Nordisk Pharmatech one of the leading suppliers of crystalline quaternary ammonium compounds (Quats) for a wide range of applications.
High levels of purity for products such as benzalkonium chloride, cetrimide, cetrimonium bromide (CTAB) makes them particularly suited for pharmaceutical applications. They act either as preservatives or active ingredients in many ophthalmic, nasal, oral, and topical drugs and in a variety of solutions, ointments, and creams. They can also be used as lysing or precipitating agents in vaccine production.
For the cosmetic industry, Novo Nordisk Pharmatech’s Quats’ purity and characteristics provide ideal conditioning, emulsifying and preserving effects in hair and cream products.
The company can also advise you about the right product for their formulation, or develop custom-designed products to meet specific application needs.